Zgwatinib

Zgwatinib (SOMG-833) is a potent, selective, and ATP-competitive c-MET inhibitor, with an IC50 of 0.93 nM against c-MET, over 10,000-fold more potent compared with 19 tyrosine kinases (including c-MET family members and highly homologous kinases) . Zgwatinib potently inhibits c-MET-driven cell proliferation. Zgwatinib as a potential candidate agent for c-MET-driven human cancers research[1].

Product Specifications

CAS Number

[1268264-10-3]

Product Name Alternative

SOMG-833

UNSPSC

12352005

Target

C-Met/HGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/zgwatinib.html

Solubility

10 mM in DMSO

Smiles

O=[N+]([O-])C1=CC(CNC2=C3C=C(C=NC3=CC(C(F)(F)F)=C2)N4CCN(CC4)C)=CC=C1

Molecular Formula

C22H22F3N5O2

Molecular Weight

445.44

References & Citations

[1]Zhang, H, et al. SOMG-833, a Novel Selective c-MET Inhibitor, Blocks c-MET-Dependent Neoplastic Effects and Exerts Antitumor Activity. Journal of Pharmacology and Experimental Therapeutics, 350 (1), 36–45.